Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Zusduri demonstrated a 72.2% 24-month response durability in LG-IR-NMIBC patients, leading to FDA approval as a non-surgical treatment option. The ENVISION trial enrolled 240 patients, focusing on ...

Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

A "first-in-class" intravesical gemcitabine (Gemzar)-releasing system holds promise as a novel bladder-sparing treatment for patients with advanced/refractory solid Bacillus Calmette-Guérin ...